Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tratamiento inmunomodulador de la enfermedad pulmonar intersticial asociada con variantes de genes relacionados con el surfactante (TIPS)

17 de septiembre de 2026 actualizado por: Assistance Publique - Hôpitaux de Paris

Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).

The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.

Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.

The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.

Main objective and primary endpoint : Main objective:

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

Primary endpoint:

Difference in forced vital capacity decline between the 2 groups at one year.

Secondary objectives and endpoints : Secondary objectives:

  1. tolerance of the triple therapy,
  2. correlation between the respiratory, radiological and clinical functional response,
  3. quality of life of the patients,
  4. overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival

Secondary endpoints:

  1. Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
  2. Thoracic CT scan and PFT at 6 months and one year after randomization
  3. Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
  4. Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care

Category : Category 2

Population of study participants: Patients aged over 18 years with ILD and SRG variant

Number of participants included : 30

Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 18 years and <80 years
  2. Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
  3. ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years

Exclusion Criteria:

  1. Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
  2. Pregnancy and breastfeeding
  3. Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
  4. Desire to have a child within 22 months
  5. Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
  6. Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
  7. No affiliation to any health insurance system
  8. Refusal to participate to the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3

The experimental treatment will be the combination of:

  • Prednisone 10 mg/day (1 tablet/day)
  • Hydroxychloroquine 400 mg/day (2 tablets/day)
  • Azithromycin 250 mg x3/week (3 tablets/week) Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no

Comparador activo: Standard of care

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in forced vital capacity decline between the 2 groups at one year.
Periodo de tiempo: 12 Months

Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.

12 Months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
tolerance of the triple therapy
Periodo de tiempo: 12 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization)

12 months
correlation between the respiratory, radiological and clinical functional response,
Periodo de tiempo: 12 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization

12 months
Quality of life of the patients
Periodo de tiempo: 12 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization,

12 months
tolerance of the triple therapy
Periodo de tiempo: 6 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

6 months
tolerance of the triple therapy
Periodo de tiempo: 3 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization)

3 months
correlation between the respiratory, radiological and clinical functional response,
Periodo de tiempo: 6 months

Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization

6 months
Quality of life of the patients
Periodo de tiempo: 9 months

Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization,

9 months
Quality of life of the patients
Periodo de tiempo: 6 months

Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization,

6 months
Quality of life of the patients
Periodo de tiempo: 3 months

Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization,

3 months
Overall survival
Periodo de tiempo: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Transplant-free survival
Periodo de tiempo: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Exacerbation free-survival
Periodo de tiempo: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
Hospitalization-free survival
Periodo de tiempo: 12 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization

12 months
tolerance of the triple therapy
Periodo de tiempo: 9 months

Clinical and biological tolerance (occurrence of an adverse effect during treatment),

9 months
tolerance of the triple therapy
Periodo de tiempo: 12 months

ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients)

12 months
tolerance of the triple therapy
Periodo de tiempo: 12 months

Ophthalmological (at one year after randomization)

12 months
tolerance of the triple therapy
Periodo de tiempo: 9 months

ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients)

9 months
tolerance of the triple therapy
Periodo de tiempo: 6 months

ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients)

6 months
tolerance of the triple therapy
Periodo de tiempo: 3 months

ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients)

3 months
Overall survival
Periodo de tiempo: 9 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization

9 months
Overall survival
Periodo de tiempo: 6 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization

6 months
Overall survival
Periodo de tiempo: 3 months

Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization

3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

11 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

27 de febrero de 2026

Publicado por primera vez (Actual)

2 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir